Pancreatic Cancer Research

ResearcherRoyal Marsden NHS Foundation TrustActive in the last 2 years

M. Hawkins

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-6669-0628; OpenAlex author ID A5023081058. Sources: ClinicalTrials.gov.

Their work

Papers
16 (first author 0, last author 7)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
2
Collaborators
41
Papers, trials and grants by year

2014: 1 paper · 2015: 1 trial · 2016: 4 papers · 2017: 1 paper · 2018: 1 paper · 2019: 1 paper · 2020: 1 paper · 2021: 3 papers · 2022: none · 2023: none · 2024: 2 papers · 2025: none · 2026: 2 papers

Papers 16

  1. Corrigendum to "SPARC, a phase-I trial of pre-operative, margin intensified, stereotactic body radiation therapy for pancreatic cancer" [Radiother. Oncol. 155 … Last author DOI 10.1016/j.radonc.2026.111610↗
  2. The OligoPanc project: an interdisciplinary expert consensus statement on oligometastatic pancreatic cancer. Co-author DOI 10.1016/s1470-2045(25)00714-4↗
  3. Radiation therapy for locally advanced pancreatic adenocarcinoma: a therapeutic option which should not be forgotten. Letter to the Editor regarding: "Pancreat… Co-author DOI 10.1016/j.annonc.2024.05.003↗
  4. Standard or high dose chemoradiotherapy, with or without the protease inhibitor nelfinavir, in patients with locally advanced pancreatic cancer: The phase 1/ra… Co-author DOI 10.1016/j.ejca.2024.114236↗
  5. ESTRO ACROP guidelines for target volume definition in pancreatic cancer. Co-author DOI 10.1016/j.radonc.2020.07.052↗
  6. SPARC, a phase-I trial of pre-operative, margin intensified, stereotactic body radiation therapy for pancreatic cancer. Last author DOI 10.1016/j.radonc.2020.11.007↗
  7. Reply to Comment on "The UK consensus position on the treatment of pancreatic cancer during the COVID-19 pandemic". Co-author DOI 10.1038/s41416-020-01133-8↗
  8. Considerations for the treatment of pancreatic cancer during the COVID-19 pandemic: the UK consensus position. Co-author DOI 10.1038/s41416-020-0980-x↗
  9. Study protocol: a multi-centre randomised study of induction chemotherapy followed by capecitabine ± nelfinavir with high- or standard-dose radiotherapy for lo… Co-author DOI 10.1186/s12885-019-5307-z↗
  10. Stomach Dose-Volume Predicts Acute Gastrointestinal Toxicity in Chemoradiotherapy for Locally Advanced Pancreatic Cancer. Last author DOI 10.1016/j.clon.2018.02.067↗
  11. Correlation of 18F-Fluorodeoxyglucose Positron Emission Tomography Parameters with Patterns of Disease Progression in Locally Advanced Pancreatic Cancer after … Last author DOI 10.1016/j.clon.2017.01.038↗
  12. ARCII: A phase II trial of the HIV protease inhibitor Nelfinavir in combination with chemoradiation for locally advanced inoperable pancreatic cancer. Co-author DOI 10.1016/j.radonc.2016.03.021↗
  13. Conformity analysis to demonstrate reproducibility of target volumes for Margin-Intense Stereotactic Radiotherapy for borderline-resectable pancreatic cancer. Last author DOI 10.1016/j.radonc.2016.08.001↗
  14. A phase-I trial of pre-operative, margin intensive, stereotactic body radiation therapy for pancreatic cancer: the 'SPARC' trial protocol. Last author DOI 10.1186/s12885-016-2765-4↗
  15. miR-21 expression and clinical outcome in locally advanced pancreatic cancer: exploratory analysis of the pancreatic cancer Erbitux, radiotherapy and UFT (PERU… Co-author DOI 10.18632/oncotarget.7208↗
  16. Challenges in using ¹⁸F-fluorodeoxyglucose-PET-CT to define a biological radiotherapy boost volume in locally advanced pancreatic cancer. Last author DOI 10.1186/1748-717x-9-146↗

Trials 1

  1. SBRT Pre-operatively for Pancreatic Cancer Principal investigator NCT02308722↗

Closest collaborators

The 25 strongest of 41 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Somnath Mukherjee · 12 shared papers, 2014–2024 · strength 1.08
  2. D. Holyoake · 8 shared papers, 2016–2026 · strength 0.98
  3. Ganesh Radhakrishna · 8 shared papers, 2016–2026 · strength 0.97
  4. Derek B. Grose · 6 shared papers, 2016–2026 · strength 0.74
  5. Pippa G. Corrie · 4 shared papers, 2019–2024 · strength 0.43
  6. Christopher Mark Jones · 3 shared papers, 2020–2024 · strength 0.35
  7. Mike Partridge · 5 shared papers, 2014–2018 · strength 0.34
  8. F. Huguet · 2 shared papers, 2021–2024 · strength 0.33
  9. Chris N Hurt · 3 shared papers, 2018–2024 · strength 0.33
  10. Thomas Baptist Brunner · 4 shared papers, 2014–2021 · strength 0.32
  11. Tim Maughan · 3 shared papers, 2016–2024 · strength 0.28
  12. Eric E. O’Neill · 3 shared papers, 2016–2024 · strength 0.28
  13. V. Vendrely · 1 shared paper, 2024 · strength 0.20
  14. Mauro Loi · 1 shared paper, 2024 · strength 0.20
  15. Anna M E Bruynzeel · 1 shared paper, 2024 · strength 0.20
  16. Marta Scorsetti · 1 shared paper, 2024 · strength 0.20
  17. Christelle Bouchart · 1 shared paper, 2024 · strength 0.20
  18. Eva Versteijne · 1 shared paper, 2024 · strength 0.20
  19. Joost J.M.E. Nuyttens · 1 shared paper, 2024 · strength 0.20
  20. James S. Good · 2 shared papers, 2020–2021 · strength 0.19
  21. Paula Ghaneh · 2 shared papers, 2020–2021 · strength 0.19
  22. Katharine L. Aitken · 2 shared papers, 2020–2021 · strength 0.19
  23. Daniel H. Palmer · 2 shared papers, 2020–2021 · strength 0.19
  24. Nigel Balfour Jamieson · 2 shared papers, 2020–2021 · strength 0.19
  25. Juan W. Valle · 2 shared papers, 2020–2021 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.